NCT04926051

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

A Phase 1, Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose, and a Japanese Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986172, Including an Open-Label Assessment of Relative Bioavailability and Food Effect on the Single-Dose Pharmacokinetics of BMS-986172 in Healthy and Obese Otherwise Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986172 and evaluate the effects of food on BMS-986172 absorption.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	BMS-986172	Specified dose on specified days
OTHER	Placebo	Specified dose on specified days

Timeline

• Start date: 2021-06-15
• Primary completion: 2021-12-28
• Completion: 2021-12-28
• First posted: 2021-06-14
• Last updated: 2022-06-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study